Multiple Sclerosis Clinical Trial
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Summary
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Full Description
The study is divided into a Core Phase, which includes the Double-Blind Treatment Period, and an Extension Phase in which all patients will be treated with fingolimod. The Core Phase is a 24-month, double-blind, randomized, active-controlled, parallel-group multicenter study phase to evaluate the efficacy and safety of fingolimod compared to IFN β-1a in children/adolescent patients aged 10-17 years old with MS. The Extension Phase is a 60-month (5 year) study phase for patients who complete the Core Phase of the study and meet all inclusion/exclusion criteria and for patients who will be recruited in the younger cohort to participate in the Extension Phase. The 'younger cohort' refers to the population of pediatric patients fulfilling any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2). The recruitment of the younger cohort (up to 25 patients) was requested as a post- approval health authority commitment
Eligibility Criteria
Key Inclusion Criteria Core Phase:
diagnosis of multiple sclerosis
at least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of Gd enhancing lesions on MRI within 6 months EDSS score of 0 to 5.5, inclusive
Key Exclusion Criteria Core Phase:
patients with progressive MS
patients with an active, chronic disease of the immune system other than MS
patients meeting the definition of ADEM
patients with severe cardiac disease or significant findings on the screening ECG.
patients with severe renal insufficiency
Key Inclusion Criteria Extension Phase:
Applies to all patients participating in the Core Phase and then entering the Extension Phase. 1. Patients that originally met Core Phase Inclusion criteria and completed the Core phase on or off of study drug.
Applies to patients newly recruited to participate in the Extension Phase.
All newly recruited patients' that enroll directly into the Extension Phase must fulfill the local country health authority product label approved for pediatric age group for inclusion criteria.
Central review (including initial MRI report) of the diagnosis of pediatric MS will be required for all newly recruited patients.
Key Exclusion Criteria Extension Phase:
Applies to patients who completed the Core Phase, but prematurely discontinued study drug.
Premature discontinuation of the study drug during the Core Phase due to:
an adverse event,
serious adverse event,
laboratory abnormality
other conditions leading to permanent study drug discontinuation due to safety reasons
Patients with known new events or concomitant medications (washout periods required prior to Visit 15) that would exclude them from the Core Phase exclusion criteria. Serological or other additional tests will not be required.
Applies to patients newly recruited in the younger cohort to participate in the Extension Phase.
1. All newly recruited patients in the younger cohort that enroll directly into the Extension Phase must fulfill the exclusion criteria for the core phase.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 107 Locations for this study
Birmingham Alabama, 35294, United States
Little Rock Arkansas, 72202, United States
San Francisco California, 94115, United States
Aurora Colorado, 80045, United States
Miami Florida, 33136, United States
Orlando Florida, 32819, United States
Tallahassee Florida, 32312, United States
Chicago Illinois, 60611, United States
Boston Massachusetts, 02114, United States
Boston Massachusetts, 02115, United States
Detroit Michigan, 48201, United States
New Brunswick New Jersey, 08901, United States
Rochester New York, 14642, United States
Stony Brook New York, 11794, United States
Chapel Hill North Carolina, 27599, United States
Durham North Carolina, 27710, United States
Philadelphia Pennsylvania, 19104, United States
Greenville South Carolina, 29607, United States
San Antonio Texas, 78229, United States
Salt Lake City Utah, 84108, United States
Parkville Victoria, 3052, Australia
Vienna , 1090, Austria
Minsk , 22011, Belarus
Belo Horizonte Minas Gerais, 30150, Brazil
Rio de Janeiro RJ, 20270, Brazil
Sao Paulo SP, 05403, Brazil
Goiania , 74605, Brazil
Sofia , 1113, Bulgaria
Calgary Alberta, T3B 6, Canada
Ottawa Ontario, K1H 8, Canada
Osijek , 31000, Croatia
Tallinn , 10617, Estonia
Bordeaux Cedex , 33076, France
Le Kremlin Bicetre , 94275, France
Marseille Cedex 05 , 13885, France
Montpellier , 34295, France
Toulouse Cedex , 31059, France
Bochum , 44791, Germany
Bonn , 53111, Germany
Dresden , 01307, Germany
Erlangen , 91054, Germany
Essen , 45147, Germany
Freiburg , 79106, Germany
Gottingen , 37075, Germany
Hamburg , 20246, Germany
Muenchen , 80337, Germany
Muenster , 48149, Germany
Bari BA, 70124, Italy
Montichiari BS, 25018, Italy
Catania CT, 95123, Italy
Milano MI, 20132, Italy
Cefalu PA, 90015, Italy
Roma RM, 00133, Italy
Roma RM, 00189, Italy
Gallarate VA, 21013, Italy
Napoli , 80131, Italy
Riga , LV-10, Latvia
Kaunas LTU, LT 50, Lithuania
Ciudad De Mexico D F, 06700, Mexico
Mexico Distrito Federal, 03310, Mexico
Mexico Distrito Federal, 04530, Mexico
Mexico Distrito Federal, 06720, Mexico
Merida Yucatán, 97125, Mexico
Rotterdam , 3015 , Netherlands
Lodz , 93-33, Poland
Lublin , 20-09, Poland
Poznan , 60-35, Poland
Wroclaw , 50 42, Poland
Santurce , 00912, Puerto Rico
Bucuresti , 04191, Romania
Kazan , 42004, Russian Federation
Moscow , 11960, Russian Federation
Moscow , 11999, Russian Federation
Novosibirsk , 63008, Russian Federation
St. Petersburg , 19711, Russian Federation
Belgrade , 11000, Serbia
Kragujevac , 34000, Serbia
Novi Sad , 21000, Serbia
Bratislava Slovensko, 83340, Slovakia
Malaga Andalucia, 29010, Spain
Sevilla Andalucia, 41009, Spain
Esplugues De Llobregat Barcelona, 08950, Spain
Barcelona Catalunya, 08035, Spain
Valencia Comunidad Valenciana, 46010, Spain
Barakaldo Pais Vasco, 48903, Spain
Vigo Pontevedra, 36212, Spain
Madrid , 28006, Spain
Madrid , 28034, Spain
Lund , 221 8, Sweden
Istanbul TUR, 34098, Turkey
Ankara , 06100, Turkey
Ankara , 06500, Turkey
Izmir , 35340, Turkey
Konak-Izmir , 35210, Turkey
Samsun , 55139, Turkey
Cherkasy , 18000, Ukraine
Dnipropetrovsk , 49027, Ukraine
Kharkiv , 61068, Ukraine
Kharkiv , 61091, Ukraine
Kiev , 03110, Ukraine
Lviv , 79010, Ukraine
Odesa , 65009, Ukraine
Vinnytsa , 21029, Ukraine
West Midlands Birmingham, B4 6N, United Kingdom
Edinburgh , EH9 1, United Kingdom
London , WC1N , United Kingdom
London , WC1N , United Kingdom
How clear is this clinincal trial information?